Thomson spent five years at Goldman Sachs as one of two analysts on the EU biotechnology research team, prior to joining the Clear River Capital hedge fund in 2009, where she responsible for pharma and biotech stock research on a healthcare-focused equity hedge fund.
Linden, who started her role at the beginning of this week, will report to Gemma Game, senior portfolio manager on the healthcare team.
Game took over as manager of the £265m Axa Framlington Health Fund earlier this year from Deane Donnigan, who is leaving the firm at the end of the month.
“Equity investors have traditionally thought of the healthcare sector as a defensive play, but factors such as the reform of healthcare provision in the US have created new opportunities for outperformance,” said Mark Beveridge, global head of Axa Framlington.
